Eli Lilly and CompanyLLY
Close of Friday, October 23, 2026 · Eli Lilly and Company is trading above its Pivot, OnlyAlpha's long-term trend line.
Price
$1,273
vs its Pivot
+17.4%
OnlyAlpha Score
70
Trend
Above its Pivot
Last 12 months. Solid line: price. Dashed green: the Pivot.
Returns
| 1 month | Year to date | 1 year | 3 years / yr | 5 years / yr |
|---|---|---|---|---|
| +7.7% | +19.1% | +57.7% | +28.9% | +41.1% |
Dividend: $6.69 a share over the last 12 months, a 0.53% yield at today's price.
Who runs and owns it
In these funds
Big investors that own it (latest 13F)
| OrbiMed | 5.9% of holdings |
| Norway (Norges Bank) | 1.4% of holdings |
| New York State Common | 1.3% of holdings |
| Canada Pension Plan | 1.1% of holdings |
| CalPERS | 1.0% of holdings |
| Citadel | 0.7% of holdings |
Suppliers, customers and partners
Sells to LLY
| Incyte | Olumiant (baricitinib) royalties |
| Halozyme | ENHANZE license |
LLY sells to
| McKesson | significant % of revenue each (XBRL: 16-24% each) |
| Cencora | significant % of revenue each (XBRL: 16-24% each) |
| Cardinal Health | significant % of revenue each (XBRL: 16-24% each) |
| Amphastar Pharmaceuticals | BAQSIMI transition services |
Partners and deals
| Boehringer Ingelheim (private) | Jardiance/Basaglar collaboration |
From the companies' own annual reports filed with the SEC.
Healthcare · Pharma
Get LLY in your free daily emailAfter every close: whether LLY is above or below its Pivot, its OnlyAlpha Score, and any new buy or sell signal, along with the rest of your list.
Track LLY free → Full Stock check
Track LLY free → Full Stock check